Immunotherapy: Understanding the “Revolution” in cancer treatment.

Cancer treatment has changed dramatically over the past two decades, and immunotherapy is one of the biggest reasons why. For many people in Singapore, the word itself can sound technical or even mysterious, but the idea behind it is straightforward. Instead of attacking cancer directly in the same way as chemotherapy, immunotherapy helps the body’s own immune system recognise and fight cancer cells more effectively. That shift has changed treatment planning for several cancer types, including some advanced cancers that were once difficult to manage with standard options alone.

For Singaporeans making healthcare decisions, the most important question is not whether immunotherapy is a miracle, but where it fits, who may benefit, what the risks are, and how it is used alongside surgery, radiotherapy, chemotherapy, targeted therapy, or supportive care. The answer depends on the cancer type, the stage of disease, biomarker test results, overall health, and treatment goals. In Singapore, these decisions are typically made by a multidisciplinary team, often involving medical oncologists, surgeons, radiation oncologists, pathologists, radiologists, pharmacists, and specialist nurses. That collaborative approach matters because immunotherapy is powerful, but it is not appropriate for every patient or every cancer.

Understanding immunotherapy begins with understanding the immune system. The immune system is designed to detect abnormal cells and remove threats. Cancer cells, however, can develop ways to hide from immune surveillance or suppress immune responses. Immunotherapy works by removing some of those “brakes” or by helping immune cells identify cancer more clearly. In practical terms, this means some cancers may respond in a way that was not possible with older treatment approaches. For patients and families in Singapore, especially those balancing work, caregiving, and treatment appointments, this can mean a different experience from conventional chemotherapy, although immune-related side effects still require close medical monitoring.

How immunotherapy works, and why it is called a breakthrough

Immunotherapy is not one single treatment. It is a broad category that includes several distinct approaches. Each one uses the immune system differently. The most established type in everyday cancer care is checkpoint inhibitor therapy. Checkpoints are natural proteins that help prevent the immune system from attacking normal tissues. Some cancers exploit these checkpoints to avoid immune attack. Checkpoint inhibitors block those signals so immune cells can respond more strongly.

Another major category is adoptive cell therapy, which includes treatments such as CAR T-cell therapy in selected blood cancers. In this approach, immune cells are collected, modified or expanded in specialised facilities, then returned to the patient to target cancer cells more effectively. There are also therapeutic cancer vaccines and cytokine-based therapies, although these are used in more limited settings. Some treatments are approved for specific cancers, while others are available only under tightly controlled protocols or specialised indications.

Checkpoint inhibitors explained in simple terms

Checkpoint inhibitors are often discussed in the context of “PD-1,” “PD-L1,” and “CTLA-4.” These are proteins involved in immune regulation. PD-1 is found on immune cells called T cells, while PD-L1 may be expressed by cancer cells or surrounding tissue. When they bind, the immune response is dampened. Drugs that block this interaction can restore immune activity. CTLA-4 is another immune checkpoint that can also be blocked in certain cancers. These treatments are not chemotherapy, and they do not work by killing cells directly in the traditional sense. Instead, they modulate the immune response against cancer.

This is why immunotherapy can produce durable responses in some patients. In selected cancers, response may continue even after treatment stops. That said, response patterns can vary. Some patients respond well, some do not respond, and some may develop resistance over time. Immunotherapy is therefore best understood as a major advance, not a universal cure.

Why biomarker testing matters before treatment starts

One of the most important changes in modern oncology is the use of biomarker testing to guide therapy. Biomarkers are measurable features of a tumour that help predict whether a treatment may work. For immunotherapy, examples can include PD-L1 expression in certain cancers, mismatch repair deficiency or microsatellite instability in some solid tumours, and specific blood cancer markers in haematologic malignancies. Testing does not guarantee response, but it helps doctors select treatments more rationally.

For Singapore patients, this means a diagnosis is no longer treated as a single label. Two people with the same cancer type may receive different treatment plans because their tumours behave differently at the molecular level. That personalised approach is one of the strongest reasons immunotherapy has become so important in cancer care.

Which cancers may be treated with immunotherapy

Immunotherapy is used in several cancer types, but not all cancers respond equally well. The most established uses include some lung cancers, melanoma, kidney cancer, bladder cancer, head and neck cancers, liver cancer, certain stomach cancers, some colorectal cancers with specific biomarkers, and several blood cancers. In Singapore, where cancer care follows evidence-based and guideline-driven practice, immunotherapy is considered according to the approved indication, stage of disease, biomarker profile, and patient suitability.

Solid tumours

In solid tumours, checkpoint inhibitors have become a standard option in multiple settings. For example, some patients with advanced non-small cell lung cancer may receive immunotherapy alone or in combination with chemotherapy, depending on biomarker results and clinical factors. In other cancers, immunotherapy may be given after surgery or radiotherapy to reduce the risk of recurrence, or it may be used when disease has spread and the goal is to control it for as long as possible.

It is also used in earlier-stage disease in selected situations. This matters because immunotherapy is not just a treatment for end-stage cancer. It can play a role across the treatment timeline. The right timing depends on disease stage, tumour biology, and the treatment plan chosen by the oncology team.

Blood cancers

Some blood cancers are treated with immunotherapy in very specialised ways. CAR T-cell therapy is one example, usually reserved for certain relapsed or refractory blood cancers after other treatments. This is a highly complex therapy that requires careful patient selection, specialised infrastructure, and close monitoring for potentially serious complications. It is not a routine outpatient treatment and is offered only in particular settings.

Monoclonal antibodies and other immune-based treatments are also important in haematology. Although these therapies may not always be described by patients as immunotherapy in the narrowest sense, they belong to the broader family of immune-directed cancer treatments.

What patients in Singapore should expect during treatment

For many Singaporean patients, a practical question is what day-to-day life looks like during immunotherapy. The answer depends on the drug, schedule, cancer type, and how the person responds. Some treatments are given by intravenous infusion in hospital or day care settings at intervals ranging from every few weeks to longer maintenance schedules. Others, in specific contexts, may be combined with oral medications or other treatments.

Compared with chemotherapy, some people find immunotherapy easier to tolerate in terms of nausea or hair loss. However, that does not mean it is free of side effects. Immune activation can cause inflammation in normal organs, which is why close follow-up is essential. Patients may continue working, caring for family, or managing everyday responsibilities, but they should plan around appointments, scans, blood tests, and symptom monitoring. In a busy Singapore lifestyle, this coordination can be challenging, so clear communication with the care team helps reduce stress and delays.

Common side effects and immune-related adverse events

The most important side effects of immunotherapy are called immune-related adverse events. This means the immune system may attack normal tissues as well as cancer. These effects can involve the skin, bowel, liver, lungs, thyroid, pituitary gland, kidneys, or other organs. Common symptoms can include rash, diarrhoea, persistent cough, breathlessness, fatigue, headache, abdominal pain, jaundice, or changes in mood and weight. Some side effects are mild, while others can be serious and require urgent treatment.

Management often involves pausing therapy and using corticosteroids or other immune-suppressing medicines when clinically indicated. Early reporting of symptoms is important. Patients should not wait for a routine appointment if they develop severe diarrhoea, chest pain, worsening shortness of breath, marked weakness, confusion, or signs of organ inflammation. In Singapore, oncology teams usually provide clear instructions on who to contact after hours and what symptoms require immediate assessment.

How follow-up is usually done

Follow-up during immunotherapy typically involves physical examination, blood tests, and imaging at intervals set by the treating team. Blood tests may monitor liver, kidney, thyroid, and other organ function. Imaging helps assess whether the cancer is shrinking, stable, or progressing. Because immune-based responses can sometimes look different from chemotherapy responses, doctors interpret scans carefully and in context with symptoms and laboratory findings.

For patients, this means sticking to appointments matters. Missing a blood test or scan can delay detection of side effects or make it harder to judge whether treatment is working. Good treatment adherence is a practical part of safety, not just a scheduling issue.

Immunotherapy in the Singapore context: access, decision-making, and realistic expectations

Singapore has a strong oncology ecosystem, with treatment delivered across public hospitals, private hospitals, and specialist cancer centres. Access to immunotherapy depends on approved indications, clinical suitability, and in some cases financial considerations. Patients often discuss treatment cost, MediSave, MediShield Life, Integrated Shield Plans, and employer benefits with their care team or hospital financial counsellors. These discussions are important because immunotherapy may involve repeated dosing over time, and planning ahead reduces uncertainty.

Another practical point is second opinions. In cancer care, especially when treatment options are complex, seeking a second opinion is a normal and reasonable step. It can help confirm the diagnosis, review biomarker results, and ensure the proposed plan aligns with the best available evidence. For Singapore residents, this can be particularly helpful when deciding between surgery, standard therapy, targeted therapy, or an immunotherapy-based approach.

Why not every patient should expect immunotherapy to work

Immunotherapy has transformed care, but response rates are not the same for every cancer or every patient. Some tumours are less visible to the immune system. Others create an environment that suppresses immune cells. Even among cancers that are approved for immunotherapy, not every patient benefits. This is why accurate staging, pathology review, molecular testing, and specialist consultation remain essential.

A careful, evidence-based view is the best one. The presence of an exciting treatment does not replace the need for good diagnostic work, realistic counselling, and close follow-up. For families hoping for a strong response, it is understandable to feel optimistic. At the same time, expectations should stay grounded in the biology of the cancer and the patient’s overall condition.

What to ask your doctor before starting treatment

If immunotherapy is being considered, patients and caregivers may find it helpful to ask focused questions during consultations. Clear questions can improve understanding and help people make informed choices. In Singapore, where consultations can be time-limited and patients may feel overwhelmed after a diagnosis, preparing ahead is especially useful.

• What type of immunotherapy is being recommended, and why is it suitable for my cancer?
• What biomarker tests were done, and what do the results mean?
• Is immunotherapy being used alone or with chemotherapy, surgery, or radiotherapy?
• What side effects should I watch for at home?
• Which symptoms mean I should seek urgent medical help?
• How often will I need blood tests, scans, or clinic reviews?
• What are the treatment goals, cure, long-term control, or symptom relief?
• Are there alternatives if immunotherapy is not suitable or does not work?

These questions are not just administrative. They help patients understand the logic of the treatment plan and prepare for what comes next. That understanding often makes the treatment journey less stressful and more manageable.

Immunotherapy represents a major step forward in cancer treatment because it uses the body’s own defence system in a more targeted and intelligent way. For some people, it can offer longer control of disease, and in selected cases, durable responses. For others, it may not be the right choice, or it may need to be combined with other treatments. The key is personalised care guided by sound pathology, biomarker testing, specialist expertise, and careful follow-up.

For Singapore readers, the most useful takeaway is simple. If immunotherapy is being discussed for you or a loved one, ask how it fits the cancer type, what the test results show, what benefits are realistic, and what side effects need urgent attention. That conversation, grounded in evidence and guided by an oncology specialist, is the best way to navigate this evolving area of cancer care.

Medical note: This article is for general health information only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare professional. Cancer treatment decisions should always be made with a doctor familiar with the patient’s full medical history and test results.